Ontology highlight
ABSTRACT:
SUBMITTER: Cortes JE
PROVIDER: S-EPMC5303616 | biostudies-literature | 2016 Dec
REPOSITORIES: biostudies-literature
Cortes Jorge E JE Khoury Hanna J HJ Kantarjian Hagop M HM Lipton Jeff H JH Kim Dong-Wook DW Schafhausen Philippe P Matczak Ewa E Leip Eric E Noonan Kay K Brümmendorf Tim H TH Gambacorti-Passerini Carlo C
American journal of hematology 20160915 12
Bosutinib is an Src/Abl tyrosine kinase inhibitor (TKI) indicated for adults with Ph+ chronic myeloid leukemia (CML) resistant/intolerant to prior TKIs. This long-term update of an ongoing phase 1/2 study evaluated the efficacy and safety of third-/fourth-line bosutinib in adults with chronic phase (CP) CML. Median durations of treatment and follow-up were 8.6 (range, 0.2-87.7) months and 32.7 (0.3-93.3) months, respectively. Cumulative confirmed complete hematologic response (cCHR) and major cy ...[more]